Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04596150
Title Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors CytomX Therapeutics
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ESP


No variant requirements are available.